![]() Idarucizumab is to be used when a patient taking dabigatran needs to undergo an emergency surgery or when life-threatening or uncontrolled bleeding occurs. The European Medicines Agency (EMA) has recommended granting a marketing authorisation for idarucizumab as a specific antidote to the anticoagulant medicine dabigatran etexilate, when rapid reversal of its effect is required.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |